Imagen de Portada

Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study

Guardado en:
Publicado en:Molecular Medicine vol. 31, no. 1 (Dec 2025), p. 5
Autor principal: Ye, Lele
Otros Autores: Long, Chunhao, Xu, Binbing, Yao, Xuyang, Yu, Jiaye, Luo, Yunhui, Xu, Yuan, Jiang, Zhuofeng, Nian, Zekai, Zheng, Yawen, Cai, Yaoyao, Xue, Xiangyang, Guo, Gangqiang
Publicado:
Springer Nature B.V.
Materias:
Medical diagnosis
Ovarian cancer
Patients
Gene expression
Cell death
Datasets
Medical prognosis
Metastasis
Mortality
Cancer therapies
Ferroptosis
Autophagy
Oncology
Genomics
Apoptosis
Pathogenesis
Precision medicine
Chemotherapy
Drug resistance
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:BackgroundPredictive, preventive, and personalized medicine (PPPM/3PM) is a strategy aimed at improving the prognosis of cancer, and programmed cell death (PCD) is increasingly recognized as a potential target in cancer therapy and prognosis. However, a PCD-based predictive model for serous ovarian carcinoma (SOC) is lacking. In the present study, we aimed to establish a cell death index (CDI)–based model using PCD-related genes.MethodsWe included 1254 genes from 12 PCD patterns in our analysis. Differentially expressed genes (DEGs) from the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) were screened. Subsequently, 14 PCD-related genes were included in the PCD-gene-based CDI model. Genomics, single-cell transcriptomes, bulk transcriptomes, spatial transcriptomes, and clinical information from TCGA-OV, GSE26193, GSE63885, and GSE140082 were collected and analyzed to verify the prediction model.ResultsThe CDI was recognized as an independent prognostic risk factor for patients with SOC. Patients with SOC and a high CDI had lower survival rates and poorer prognoses than those with a low CDI. Specific clinical parameters and the CDI were combined to establish a nomogram that accurately assessed patient survival. We used the PCD-genes model to observe differences between high and low CDI groups. The results showed that patients with SOC and a high CDI showed immunosuppression and hardly benefited from immunotherapy; therefore, trametinib_1372 and BMS-754807 may be potential therapeutic agents for these patients.ConclusionsThe CDI-based model, which was established using 14 PCD-related genes, accurately predicted the tumor microenvironment, immunotherapy response, and drug sensitivity of patients with SOC. Thus this model may help improve the diagnostic and therapeutic efficacy of PPPM.
ISSN:1076-1551
1528-3658
DOI:10.1186/s10020-024-01036-x
Fuente:Health & Medical Collection